Since full backbone resonance assignments were hampered by the molecular weight and instability of AlbAS-albicidin over several days, we attempted to assign the Trp signals by generating eight single Trp-to-Phe mutants (W5F, W27F, W56F, W110F, W133F, W162F, W195F, W203F), thus anticipating the loss of a single HSQC cross peak for each mutant. The instability of the mutants, the inherent protein dynamics and the close vicinity of Trp residues in the complex usually caused the loss of more than one signal for each mutant and to non-trackable chemical shift changes, which impeded an unambiguous assignment. However, the combined information from all spectra and the knowledge of the relative positions of all Trp residues in the crystal structure helped us to tentatively assign the Trp signals as shown in B. The blue spectrum shows AlbAS in the absence of albicidin. Dashed lines indicate ambiguity. Signals marked with an asterisk represent backbone amides identified by 3D HNCO and HNCA experiments, whereas Trp Hε-Nε signals were further confirmed by tryptophan-selective 2D MUSIC experiments (Standard Bruker pulse sequences). Figure 3E ) shows AlbAS (black) in 95% buffer/5% DMSO, unbound-AlbAS blank in 100% buffer without compound (blue) and AlbAS with albicidin (red). The following spectra show AlbAS (black) with the corresponding titrated compound (red). AlbAS-albicidin measurements were performed on five different samples and a representative experiment is shown in the figure. The NMR measurements using albicidin derivatives were conducted once. Supplementary Figure 18 Model of the binding mechanism of AlbAS. In the absence of albicidin, AlbAS undergoes inherent domaindomain motions on the micro-to-millisecond timescale. In this conformational ensemble, the N-terminal HTH domain is not competent for DNA binding. Upper lane: Initial anchoring of the C-terminal segment of albicidin is mediated via the CTD of AlbAS (the salt-bridge between R181 of AlbAS and building block F of albicidin is indicated by the charges). The subsequent binding of the NTD to the N-terminal segment of albicidin is highly cooperative giving an effective Kd for the entire binding process of ≤ 5.6 ± 0.2 nM. Only this mutual fixation of the NTD and CTD causes the HTH to adopt a DNA-binding competent state. Drug binding and transcriptional regulation of MerR-related genes are thus strongly coupled. Lower lane: C-terminal fragments of albicidin (here compound 5), which are still strongly captured by the CTD (Kd of approx. 55.5 ± 3.6 nM), do not or only inefficiently bridge the CTD and NTD. The HTH domain is thus decoupled from the drug-binding event and is not able to initiate transcription. Notably, in the case of AlbAL, these processes occur in a functional dimer capable of DNA binding after albicidin capture. 
Supplementary Figure 7 SEC-MALS measurements of AlbAS
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